A 76-point gap between treatment arms is not the kind of number regulators ignore. In BridgeBio‘s Phase 3 CALIBRATE study, 76% of patients on encaleret achieved simultaneous serum and urine calcium targets at Week 24, against 4% on conventional therapy (p<0.0001). That delta carried the program through NDA submission, and on July 22, 2026, the FDA formally accepted BridgeBio’s application, assigning a PDUFA target action date of May 8, 2027. The acceptance is a procedural checkpoint, not an approval, but in a disease this rare, the signal-to-noise ratio at this stage matters enormously.
Autosomal dominant hypocalcemia type 1 is driven by gain-of-function mutations in the calcium-sensing receptor gene, which locks the CaSR in an overactive state and suppresses parathyroid hormone secretion below what the body needs to regulate calcium properly. Conventional management, largely built around calcium supplements and active vitamin D analogs, corrects serum calcium imperfectly while driving urinary calcium high enough to cause nephrocalcinosis and renal impairment over time. Encaleret works as a negative allosteric modulator of the CaSR, classified as a calcilytic agent, blocking the overactivated receptor to restore PTH-mediated calcium homeostasis rather than simply flooding the system with substrate. The mechanistic distinction is what makes the CALIBRATE primary endpoint compelling: it required both serum and urine calcium to normalize simultaneously, which conventional therapy structurally cannot achieve without trading one imbalance for another.
The FDA’s acceptance without a request for additional studies is a meaningful read on the submission’s completeness, though the review period itself will test whether the agency views the Week 24 responder data as sufficient for a rare endocrine indication. ADH1 affects a small patient population, which creates pressure on labeling language and post-marketing commitments. BridgeBio will also need to demonstrate that the urine calcium benefit translates into reduced nephrocalcinosis risk over longer follow-up, a question the PDUFA review timeline may or may not resolve definitively before approval.
The single number to watch between now and May 2027 is whether the FDA requests a complete response related to renal outcomes data. If the agency is satisfied with surrogate endpoint normalization alone, encaleret’s path to approval is straightforward. If it wants longer-term nephrology evidence, the timeline extends and BridgeBio faces a more complex label negotiation. That distinction, not the acceptance itself, defines the real regulatory risk still sitting in this program.
Source link: https://www.sec.gov/Archives/edgar/data/1743881/000114036126029291/ef20078442_form8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
